Skip to content

IBD and Cannabinoid Medicine

IBD and Cannabinoid Medicine

With an estimated 3.1 million adults diagnosed with Irritable Bowel Disease (IBD) in the United States, it’s natural that many people are asking about the possible benefits of cannabis for the symptoms associated with IBD. In fact, the University of Michigan Health Department received so many questions regarding this issue, that they released a Q&A with one of their gastroenterologists on the subject. 

People suffering from IBD often have symptoms that can easily interfere with life’s daily activities.  Those symptoms include:

  • Abdominal cramps and pain
  • Diarrhea that may be bloody
  • Severe urgency to have a bowel movement
  • Fever
  • Weight loss
  • Loss of appetite
  • Iron deficiency anemia due to blood loss

With many states that allow medical marijuana including IBD in their ‘qualifying conditions’ list, patients have been able to use cannabinoid medicine in conjunction with their traditional treatment to find symptom relief.  Our data at Arfinn Med indicates that patients adding cannabinoid treatment to their regiment have seen an improvement in their symptoms, indicating a 3.9 out of 5.0 on our symptom relief scale.

A screenshot of a cell phone

Description automatically generated

If you are suffering from IBD and are interested in learning more about cannabinoid medicine, please reach out to your physician to discuss ways of incorporating it into your existing treatment. If your physician would like more information, please refer them to Arfinn Med and its EMR and data portal focusing on complimentary and alternative medicines (CAM).

Resources:

https://healthblog.uofmhealth.org/digestive-health/cannabis-for-treating-ibd-hope-or-hype

https://www.webmd.com/ibd-crohns-disease/inflammatory-bowel-syndrome#1

https://www.healthline.com/health/crohns-disease/facts-statistics-infographic#1

Stories you may be interested in

Medical Cannabis and Breast Cancer

October is breast cancer awareness month and we at Arfinn Med would like to reiterate the importance of early screening and regular tests.  According to the American Cancer Society: “Breast cancer is the most common cancer in American women, except for skin cancers. Currently, the average risk of a woman in the United States developing breast…
Read More

Cannabis and Mental Health: Social Anxiety Disorder

Social anxiety may sound like something we all experience at times in life, and that is true. It is natural for a person to feel nervous or anxious in situations like being alone in a new place or going on a first date. But for those living with social anxiety disorder, those instances of anxiety…
Read More

Norfolk research company plans clinical trials using medical marijuana

Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions. Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer.…
Read More

Three Key Voices in the Medical Marijuana Industry

As medical marijuana programs continue to expand throughout the United States, it is important to recognize some of the key voices throughout the industry that got us here. These individuals range from researches to physicians and even to patients who started their own advocacy group. Keep reading to learn about just three of the many…
Read More

Combating Opioid Dependence

The opioid epidemic is a hot topic across the United States, along with the alternatives that could alleviate the tragic consequences the epidemic brings. Opioids, also known as narcotics, are strong prescription pain relievers such as oxycodone, hydrocodone and fentanyl. Although illegal, heroin is also considered to be an opioid. Most patients are introduced to…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Leave a Comment

You must be logged in to post a comment.